SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 1,227.11 |
Enterprise Value ($M) | 1,308.82 |
Book Value ($M) | 476.81 |
Book Value / Share | 24.57 |
Price / Book | 2.57 |
NCAV ($M) | 102.85 |
NCAV / Share | 5.30 |
Price / NCAV | 11.93 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | 0.05 |
Return on Assets (ROA) | 0.04 |
Return on Equity (ROE) | 0.08 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 3.12 |
Current Ratio | 3.95 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 540.56 |
Assets | 914.52 |
Liabilities | 437.71 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 486.82 |
Operating Income | 49.53 |
Net Income | 18.78 |
Earnings Per Share Basic And Diluted | n/a |
Earnings Per Share Diluted | n/a |
Earnings Per Share Basic | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | 118.96 |
Cash from Investing | -18.51 |
Cash from Financing | 67.44 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13D/A | Meridian Venture Partners II GP, L.P. | 6.90 | -13.88 | |
13G | Vanguard Group Inc | 6.31 | ||
13G | Rubric Capital Management LP | 5.51 | ||
13G/A | BlackRock Inc. | 12.40 | 27.30 | |
13D/A | Esjay LLC | 4.80 | -4.83 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
30,574 | 154,104 | 19.84 | |
20,304 | 107,120 | 18.95 | |
21,628 | 122,945 | 17.59 | |
35,259 | 253,660 | 13.90 | |
13,476 | 99,010 | 13.61 | |
(click for more detail) |
Similar Companies | |
---|---|
AFMD – Affimed N.V. | ALIM – Alimera Sciences, Inc. |
ALT – Altimmune, Inc. | APGE – Apogee Therapeutics, Inc. |
APLT – Applied Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io